Physician profile
Sandra S Halbruner
NPI 1962469320
$1,650.04
in general payments reported to CMS, 2019-2025
13 companies · $903 in 2025
The $903 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2024: $143 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $233.10 | 2025 | Repatha |
| Axsome Therapeutics, INC. | $195.27 | 2025 | Auvelity |
| Zoll Respicardia, INC. | $151.53 | 2021 | |
| Biomerieux INC | $143.00 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Abbott Laboratories | $131.46 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Avadel Cns Pharmaceuticals, LLC | $123.98 | 2025 | Lumryz |
| Biohaven Pharmaceuticals, INC. | $120.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $115.34 | 2021 | |
| Alexion Pharmaceuticals, INC. | $111.77 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $109.62 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $109.62 | 2025 | Wegovy |
| Gilead Sciences, INC. | $85.94 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Halbruner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.